Mineralys Therapeutics (MLYS) Other financing activities (2023 - 2026)
Mineralys Therapeutics (MLYS) posted Other financing activities of $4.1 million for Q1 2026, up 2955.63% sequentially from -$142000.0 in Q4 2025, and up 3196.75% YoY from $123000.0 in Q1 2025.
Mineralys Therapeutics (MLYS) Other financing activities (2023 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Other financing activities for 4 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Other financing activities rose 3196.75% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 103.4% YoY) and the FY2024 annual result came in at $221000.0, changed N/A from the prior year.
- Other financing activities rose to $4.1 million in Q1 2026 per MLYS's latest filing, from -$142000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $203.0 million in Q3 2023 and troughed at -$203.0 million in Q4 2023.
- A 4-year average of $388727.3 and a median of $83000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2025 and 2026: Other financing activities slumped 271.08% in 2025, then soared 3196.75% in 2026.
- Over 4 years, Other financing activities stood at -$203.0 million in 2023, then jumped by 100.04% to $83000.0 in 2024, then plunged by 271.08% to -$142000.0 in 2025, then jumped by 2955.63% to $4.1 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $4.1 million, -$142000.0, and $142000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 4.06 Mn |
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | -142,000.00 |
| Dec 31, 2025 | -142,000.00 |
| Sep 30, 2025 | 142,000.00 |
| Sep 30, 2025 | 142,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | -115.92 Mn |
| Sep 30, 2024 | -115.92 Mn |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | 116.12 Mn |
| Mar 31, 2024 | 116.12 Mn |